Direxion Daily S&P Biotech Bull 3X Shares LABU
Set alert
247.22 USD -9.74 -3.79%
At close · Oct 30
247.00 -0.22 -0.09%
After hours · Oct 30, 7:29 PM ET
239.28 Day range 264.75
108.90 52-week range 341.93
- YTD
- +55.10%
- 1 year
- +92.76%
- Open
- 251.50
- Prev close
- 256.96
- Mkt cap
- 1.37B
- Vol
- 298.06K
- Avg vol
- 398.38K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 239.28
- High
- 264.75
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 262.35
- 200-d avg
- 216.17
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 262.35
- 200-day average
- 216.17
Analyst view
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
About Direxion Daily S&P Biotech Bull 3X Shares
The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.
News
- Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million
- Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
- LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout
- Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now
- 34,270 Shares in Direxion Daily S&P Biotech Bull 3x Shares $LABU Purchased by JPMorgan Chase & Co.
- Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Shares Gap Down – Here’s Why
- Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026
- Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Hits New 1-Year High – What’s Next?
- Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs
- Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Reaches New 52-Week High – What’s Next?
Your note
Sign in to keep a note on LABU — it syncs with the Stock Master app.